Spreading Depolarization as a Therapeutic Target in Severe Ischemic Stroke: Physiological and Pharmacological Strategies.

Lily ChauHerbert T DavisThomas JonesDiana Greene-ChandosMichel TorbeyC William ShuttleworthAndrew P Carlson

Published in: Journal of personalized medicine (2022)

Fluctuations in physiological variables can be associated with risk of SD after MHS. Ketamine was also found to completely inhibit SD in one subject. These data suggest that use of physiological optimization strategies and/or pharmacologic therapy could inhibit SD in MHS patients, and thereby limit edema and infarct progression. Clinical trials using individualized approaches to target this novel mechanism are warranted.

Keyphrases

clinical trial
end stage renal disease
newly diagnosed
ejection fraction
acute myocardial infarction
peritoneal dialysis
atrial fibrillation
stem cells
early onset
pain management
open label
deep learning
phase ii
drug induced
smoking cessation